Table 1

Characteristics of Abstracted studies

Author, yearRegionPatients with T2DMControlMeasurement typeStudy typeNOS
No.Age
(mean±SD) years
% femaleBMIFGF-21 level
(pg/mL)
No.Age
(mean±SD) years
% femaleBMIFGF-21 level
(pg/mL)
Akour et al, 2016Jordan10351.0±3.8NA27.63009551.0±3.8NA32.7200ELISACase–control8
Esteghamati et al, 201619 Iran4455.0±12.052.330.6103.54253.5±14.059.525.899ELISACross-sectional7
Shafaei et al, 201520 Iran6048.5±6.8NA32.96226052.2±9.8NA26.2533.9ELISACase–control7
Lin et al, 201421 China11760.3±10.246.224.9542.36858.5±11.345.625.7125.9ELISACase–control8
Xiao et al, 201222 China7755.3±8.945.524.7381.27554.9±8.345.321.0301.4ELISACase–control8
Wang et al, 201223 China11149.0±6.053.224.932108751.0±10.052.923.71520RIACross-sectional7
Jian et al, 201125 China15865.7±10.346.824.0492.35065.3±8.05225.6467.89ELISACase–control8
Cheng et al, 201125 China5455.0±11.042.624.2361.83553.0±11.054.323.2185.89ELISACase–control7
Li et al, 200926 USA3058.8±6.86023.518103057.9±6.563.323.91520RIACase–control7
Chen et al, 200827 China4453.0±11.04524.618203548.0±12.04324.71530RIACase–control7
Li et al, 200828 China6852.0±12.0NA33.328205250.0±13.0NA23.32280RIACase–control7
  • BMI, body mass index;ELISA, enzyme-linked immunosorbent assay;NA, not available;NOS, Newcastle-Ottawa Scale;RIA, radioimmunoassay.